Rohit Katial is a Rheumatology/Immunology physician affiliated with National Jewish Health. OpenAlex indexes 229 publications with 5,100 citations (h-index 35); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1400 Jackson St
Denver, CO 802062761
Telephone
303-388-4461Provider last certified this registry record 23 Feb 2021.
Clinical trials
- Sub-Sensitivity to Long-Acting Bronchodilators (LABA)
Sponsor: National Jewish Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year2025139 payments$155,175openpaymentsdata.cms.gov ↗
- Regeneron Healthcare Solutions, Inc.Program year202519 payments$32,340openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year202518 payments$28,093openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
64.9%Corticosteroid38.1%Symbicort70%Arnuity Ellipta30%Part D<11 patientsInterleukin-5 Receptor alpha-directed Cytolytic Antibody15.5%Fasenra Pen100%Part D<11 patients+ 1 more class in this area
Dermatology
35.1%Interleukin-4 Receptor alpha Antagonist35.1%Dupixent Pen68%Dupixent Syringe32%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults
American Journal of Respiratory and Critical Care Medicine
2024 - Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme
European Respiratory Journal
2024 - Exploring Definitions and Predictors of Response to Biologics for Severe Asthma
The Journal of Allergy and Clinical Immunology In Practice
2024 - Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial
European Respiratory Journal
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Donald Leung, MD
National Jewish Health
James Crapo, MD
National Jewish Health
Barry Make, MD
National Jewish Health
Charles Daley, MD
National Jewish Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”